Gt Biopharma Stock Price on December 10, 2024
| GTBP Stock | USD 2.74 0.06 2.14% |
Below is the normalized historical share price chart for GT Biopharma extending back to November 05, 1984. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of GT Biopharma stands at 2.74, as last reported on the 12th of December 2024, with the highest price reaching 3.29 and the lowest price hitting 2.74 during the day.
If you're considering investing in GTBP Stock, it is important to understand the factors that can impact its price. GT Biopharma appears to be risky, given 3 months investment horizon. GT Biopharma retains Efficiency (Sharpe Ratio) of 0.0951, which attests that the entity had a 0.0951% return per unit of price deviation over the last 3 months. We have found twenty-eight technical indicators for GT Biopharma, which you can use to evaluate the volatility of the firm. Please utilize GT Biopharma's Standard Deviation of 5.01, market risk adjusted performance of (5.26), and Semi Deviation of 4.57 to validate if our risk estimates are consistent with your expectations.
At this time, GT Biopharma's Other Stockholder Equity is relatively stable compared to the past year. As of 12/12/2024, Issuance Of Capital Stock is likely to grow to about 10.2 M, while Common Stock Shares Outstanding is likely to drop slightly above 1.3 M. . As of 12/12/2024, Price To Sales Ratio is likely to drop to 2,293. In addition to that, Price Earnings Ratio is likely to grow to -1.29. GTBP Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 22nd of September 2017 | 200 Day MA 3.1278 | 50 Day MA 2.6253 | Beta 0.57 |
GTBP |
Sharpe Ratio = 0.0951
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | GTBP | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.09 actual daily | 45 55% of assets are more volatile |
Expected Return
| 0.48 actual daily | 9 91% of assets have higher returns |
Risk-Adjusted Return
| 0.1 actual daily | 7 93% of assets perform better |
Based on monthly moving average GT Biopharma is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of GT Biopharma by adding it to a well-diversified portfolio.
Price Book 3.2423 | Book Value 5.414 | Enterprise Value -3.8 M | Enterprise Value Ebitda (0.09) | Shares Float 1.7 M |
Related Headline
Virax Biolabs Headline on 10th of December 2024
Virax Biolabs Announces Agreement with Tebubio to Expand Dis... by finance.yahoo.com
Virax Biolabs Group Limited , an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that it has entered into a non-exclusive distribution agreement with French company Tebubio to expand the distribution of its ImmuneSelect Research Use portfolio into countries in the European Union, as well as in Norway and Switzerland.
GT Biopharma Valuation on December 10, 2024
It is possible to determine the worth of GT Biopharma on a given historical date. On December 10, 2024 GTBP was worth 2.84 at the beginning of the trading date compared to the closed value of 3.04. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of GT Biopharma stock. Still, in general, we apply an absolute valuation method to find GT Biopharma's value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of GT Biopharma where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against GT Biopharma's related companies.
| Open | High | Low | Close | Volume | |
| 2.60 | 2.68 | 2.58 | 2.68 | 5,518 | |
12/10/2024 | 2.84 | 3.07 | 2.69 | 3.04 | 27,085 |
| 3.13 | 3.39 | 2.80 | 2.80 | 50,511 |
| Backtest GT Biopharma | | | GT Biopharma History | | | GT Biopharma Valuation | Previous | Next |
GT Biopharma Trading Date Momentum on December 10, 2024
| On December 11 2024 GT Biopharma was traded for 2.80 at the closing time. The top price for the day was 3.39 and the lowest listed price was 2.80 . The trading volume for the day was 50.5 K. The trading history from December 11, 2024 was a factor to the next trading day price decrease. The overall trading delta against the next closing price was 7.89% . The overall trading delta against the current closing price is 3.29% . |
GT Biopharma Fundamentals Correlations and Trends
By evaluating GT Biopharma's financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among GT Biopharma's main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. GTBP financial account trend analysis is a perfect complement when working with valuation or volatility modules.About GT Biopharma Stock history
GT Biopharma investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for GTBP is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in GT Biopharma will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing GT Biopharma stock prices may prove useful in developing a viable investing in GT Biopharma
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 1.3 M | 1.3 M | |
| Net Loss | -52.2 M | -54.8 M |
GT Biopharma Stock Technical Analysis
GT Biopharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
GT Biopharma Period Price Range
Low | December 12, 2024
| High |
0.00 | 0.00 |
GT Biopharma cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
GT Biopharma December 12, 2024 Market Strength
Market strength indicators help investors to evaluate how GT Biopharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading GT Biopharma shares will generate the highest return on investment. By undertsting and applying GT Biopharma stock market strength indicators, traders can identify GT Biopharma entry and exit signals to maximize returns
GT Biopharma Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for GT Biopharma's price direction in advance. Along with the technical and fundamental analysis of GTBP Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of GTBP to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.0923 | |||
| Jensen Alpha | 0.5836 | |||
| Total Risk Alpha | (0.22) | |||
| Sortino Ratio | 0.09 | |||
| Treynor Ratio | (5.27) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Additional Tools for GTBP Stock Analysis
When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.